SUPPORTING STATEMENT Pfizer says it takes an active role in supporting policymakers who “share in our purpose and position us to better deliver these same ideals.”¹ We applaud Pfizer’s disclosure regarding its political spending. That said, candidates, trade associations and other organizations to which Pfizer belongs or contributes may take positions that undermine its strategy or long-term financial prospects. We therefore believe that Pfizer should periodically evaluate the alignment of its political spending with their business. Pfizer includes vaccines as one of its four “areas of focus,” making up approximately 20% of Pfizer’s total revenue. Recently, policies have gained momentum at the state and federal levels that could undermine the health benefits of vaccines. Hundreds of bills have been introduced in state legislatures in 2024 and 2025 to weaken vaccination requirements and criminalize “vaccine harm,” among other topics.² Some bills promote disinformation about vaccines by designating products using mRNA technology as “weapons of mass destruction”³ or implying that mRNA vaccines alter DNA or result in the implantation of a chip under the recipient’s skin.⁴ Pfizer recognizes potential changes to vaccine or other healthcare policy in the United States could result in increased risk to its business.⁵ Yet the company has contributed to the authors of such bills, including a New York state bill to bar governmental entities from requiring the COVID 19 vaccine,⁶ a Missouri bill prohibiting educational institutions from requiring the COVID 19 vaccine or “gene therapy,”⁷ a Pennsylvania bill seeking to prohibit the requirement of vaccinations by certain public and private entities,⁸ and an Idaho bill expanding exemptions for students of majority age.⁹ Such bills, including those referencing the COVID 19 vaccine, suggest efforts to undermine vaccination regulations broadly, threatening Pfizer’s core vaccine business. Pfizer also belongs to the Pharmaceutical Research and Manufacturers of America trade association, which spent over $543,000 of Pfizer’s 2024 dues on participation or intervention in political campaigns on behalf of or in opposition to candidates for public office. Such indirect contributions are important to monitor because the interests of companies and their trade associations may not be fully aligned. An alignment report, as requested in this proposal, would give Pfizer the opportunity to better manage risks associated with misaligned political spending, which are higher than ever, and allow shareholders to evaluate the quality of Pfizer’s internal procedures and board oversight of political spending.